MicroRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor γ

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 1017-1024

  Li, Xiaofei ^a   Chen, Yongxin ^a   Wu, Shuang ^a   He, Jinke ^a   Lou, Lianqing ^a   Ye, Weiwei ^a   Wang, Jinhe ^a  

^a YIWU CENTRAL HOSPITAL   (China)

Author keywords

Hepatic stellate cells; Liver fibrosis; Microrna 34a; MicroRNA 34c; Peroxisome proliferator activated receptor

Indexed keywords

ACTA2 PROTEIN, HUMAN; ACTIN; MICRORNA; MIRN34 MICRORNA, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

BIOLOGY; DOWN REGULATION; GENETICS; HUMAN; LIVER CIRRHOSIS; METABOLISM; PATHOPHYSIOLOGY; STELLATE CELL; TUMOR CELL LINE; UPREGULATION;

ACTINS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MICRORNAS; PPAR GAMMA; UP-REGULATION;

EID: 84916229794     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2846     Document Type: Article

References (39)

1. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
2. Moreira RK: Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 131: 1728-1734, 2007.
3. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
4. Wiggins JF, Ruffino L, Kelnar K, et al: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930, 2010.
5. Raisch J, Darfeuille-Michaud A and Nguyen HT: Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol 19: 2985-2996, 2013.
6. Vettori S, Gay S and Distler O: Role of MicroRNAs in Fibrosis. Open Rheumatol J 6: 130-139, 2012.
7. Noetel A, Kwiecinski M, Elfimova N, Huang J and Odenthal M: microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 3: 49, 2012.
8. Katayama Y, Maeda M, Miyaguchi K, et al: Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncol Lett 4: 817-823, 2012.
9. He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134, 2007.
10. Chen F and Hu SJ: Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 26: 79-86, 2012.
11. Trang P, Wiggins JF, Daige CL, et al: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122, 2011.
12. Pang RT, Leung CO, Lee CL, et al: MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1. BMC Cancer 13: 25, 2013.
13. Yan K, Gao J, Yang T, et al: MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 7: e33778, 2012.
14. Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al: Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437-1446, 2010.
15. Li WQ, Chen C, Xu MD, et al: The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J 278: 1522-1532, 2011.
16. Guo CJ, Pan Q, Li DG, Sun H and Liu BW: miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J Hepatol 50: 766-778, 2009.
17. Murakami Y, Toyoda H, Tanaka M, et al: The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6: e16081, 2011.
18. Kota J, Chivukula RR, O'Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017, 2009.
19. Hazra S, Xiong S, Wang J, et al: Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279: 11392-11401, 2004.
20. Sharvit E, Abramovitch S, Reif S and Bruck R: Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. PLoS One 8: e76541, 2013.
21. Attia YM, Elalkamy EF, Hammam OA, Mahmoud SS and El-Khatib AS: Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection. Parasit Vectors 6: 199, 2013.
22. Bruck R, Weiss S, Aeed H, Pines M, Halpern Z and Zvibel I: Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor. Dig Dis Sci 54: 292-299, 2009.
23. Zhang F, Kong D, Lu Y and Zheng S: Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside. Cell Mol Life Sci 70: 259-276, 2012.
24. Guo GH, Tan DM, Zhu PA and Liu F: Hepatitis B virus X protein promotes proliferation and upregulates TGF-beta1 and CTGF in human hepatic stellate cell line, LX-2. Hepatobiliary Pancreat Dis Int 8: 59-64, 2009.
25. Weiskirchen R and Gressner AM: Isolation and culture of hepatic stellate cells. Methods Mol Med 117: 99-113, 2005.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
27. Mao CD and Byers SW: Cell-context dependent TCF/LEF expression and function: alternative tales of repression, de-repression and activation potentials. Crit Rev Eukaryot Gene Expr 21: 207-236, 2011.
28. Cha YH, Kim NH, Park C, Lee I, Kim HS and Yook JI: MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 11: 1273-1281, 2012.
29. Busser B, Sancey L, Brambilla E, Coll JL and Hurbin A: The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 1816: 119-131, 2011.
30. Lee AH, Scapa EF, Cohen DE and Glimcher LH: Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496, 2008.
31. Hanhoff T, Lücke C, Spener F: Insights into binding of fatty acids by fatty acid binding proteins. Mol Cell Biochem 239: 45-54, 2002.
32. Kaller M, Liffers ST, Oeljeklaus S, et al: Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 10: M111.010462, 2011.
33. Marra F, Efsen E, Romanelli RG et al: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119: 466-78, 2000.
34. Inagaki Y, Okazaki I: Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56: 284-292, 2007.
35. Yang S, Li Y, Gao J et al: MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32: 4294-4303, 2013.
36. Castro RE, Ferreira DM, Afonso MB, et al: miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 58: 119-125, 2013.
37. Meng F, Glaser SS, Francis H et al: Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol 181: 804-817, 2012.
38. Pineau P, Volinia S, McJunkin K et al: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 107: 264-269, 2009.
39. Qian J, Niu M, Zhai X, Zhou Q and Zhou Y: β-Catenin pathway is required for TGF-beta1 inhibition of PPARγ expression in cultured hepatic stellate cells. Pharmacol Res 66: 219-225, 2012.